Polycythemia Vera
Show Only Open Trials
1.
Phase 1/2, Open-label, Dose-escalation, Multi-ctr Study to Assess Safety, Tolerability, PK, & PD of Oral NS-018 in Patients w/ Primary Myelofibrosis, Post polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis
- Study Status: Open to Enrollment
- Sponsor: NS Pharma
- Disease Status and/or Stage: Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
2.
Phase II Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a diagnosis of Intermediate-2 or High-Risk PM, Post-PV Myelofibrosis, or Post-ET Myelofibrosis
- Study Status: Closed to Enrollment
- Sponsor: Sanofi Aventis
3.
A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms
- Study Status: Open to Enrollment
- Sponsor: Ely Lilly
- Disease Status and/or Stage: Polycythemia Vera (PV), Essential Thrombocythemia (ET), or Myelofibrosis (MF)
4.
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
- Study Status: Open to Enrollment
- Sponsor: Myeloproliferative Disorders-Research Consortium
- Disease Status and/or Stage: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
- Protocol ID: MPD-RC 111
5.
Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)
- Study Status: Closed to Enrollment
- Sponsor: Incyte Corporation
- Disease Status and/or Stage: Polycythemia Vera (PV)
6.
Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
- Study Status: Closed to Enrollment
- Sponsor: Incyte Corporation
- Disease Status and/or Stage: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
7.
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
- Study Status: Closed to Enrollment
- Sponsor: Myeloproliferative Disorders-Research Consortium
- Disease Status and/or Stage: Polycythemia Vera (PV)